PPCB
Propanc Biopharma, Inc.Company Information
- Company Name
- Propanc Biopharma, Inc.
- CIK
- CIK0001517681
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- PPCB: Nasdaq
- Fiscal Year End
- June 30
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- PPCB
SEC filing data through
Insider Sentiment
- Last purchase
- 2012-08-23
- Last sale
- 2013-07-05
- Shares purchased (TTM)
- 250,000
- Shares sold (TTM)
- 55,000
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 37,653
- Shares outstanding
- 897,099
- Ownership
- 4.20%
Earnings Market Reaction
- Filing date
- 2026-09-25
- Price on filing date
- —
- 1-month reaction
- Pending
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 9 | 8 | 8 | 9 | 8 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense Current | 8 | 1 | 7 | 8 | 8 | 10 | - | - | - | - | - | - | ||||||
| Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | - | - | - | ||||||
| Deferred Costs | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | ||||||
| Prepaid Expense Noncurrent | 4 | 0 | 7 | 9 | 11 | 13 | - | - | - | - | - | - | ||||||
| Deposits Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | - | - | - | ||||||
| Property Plant And Equipment Net | - | 0 | 0 | 0 | - | - | - | - | - | - | 0 | 0 | ||||||
| Assets | 13 | 14 | 15 | 18 | 20 | 23 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Accounts Payable And Other Accrued Liabilities Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Interest Payable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Notes Payable Current | - | - | - | - | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Liabilities Current | ||||||||||||||||||
| Convertible Debt Current | - | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | ||||||
| Liabilities Current | 3 | 3 | 4 | 4 | 6 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | ||||||
| Warrants And Rights Outstanding | - | 0 | 0 | - | - | - | - | - | - | - | - | - | ||||||
| Derivative Liabilities | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Embedded Derivative Fair Value Of Embedded Derivative Liability | - | 0 | 0 | - | - | - | - | - | - | - | - | - | ||||||
| Employee Related Liabilities Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Long Term Loans Payable | - | - | - | - | 0 | - | - | - | 0 | - | - | - | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | ||||||
| Liabilities | 3 | 4 | 4 | 4 | 6 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | 1 | 1 | - | - | - | - | - | - | - | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 153 | 149 | 144 | 144 | 138 | 138 | 62 | 61 | 62 | 61 | 61 | 61 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 9 | 10 | 10 | 14 | 14 | 18 | -4 | -4 | -4 | -4 | -4 | -3 | ||||||
| Stockholders Equity Note Subscriptions Receivable | - | - | - | - | - | - | - | - | - | - | -0 | - | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Retained Earnings Accumulated Deficit | -144 | -141 | -134 | -130 | -126 | -122 | -67 | -67 | -67 | -66 | -66 | -65 | ||||||
| Treasury Stock Value | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Liabilities And Stockholders Equity | 13 | 14 | 15 | 18 | 20 | 23 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Authorized | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 10,000 | 10,000 | 10,000 | 10,000 | 10,000 | 10,000 | 10,000 | 10,000 | 10,000 | 10,000 | 10,000 | 10,000 | ||||||
| Common Stock Shares Issued | 3 | 1 | 1 | 1 | 0 | 0 | 0 | 28 | 0 | 4 | 1 | 1 | ||||||
| Shares Outstanding | 3 | 1 | 1 | 1 | 0 | 0 | 0 | 28 | 0 | 4 | 1 | 1 | ||||||
Select a line item above to chart it.
Recent filings
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialPropanc Biopharma, Inc. (PPCB) — SEC Financial Statements & Analysis
Propanc Biopharma, Inc. (PPCB) is a pharmaceutical preparations company, incorporated in DE. Propanc Biopharma, Inc. trades on Nasdaq as: PPCB. Propanc Biopharma, Inc. (PPCB)'s most recent SEC filing is a Form 10-K for the period ended 2026-06-30, filed with the SEC on 2026-09-25. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Propanc Biopharma, Inc. carries a market cap of $1.69M, a P/E ratio of -0.09x, a P/B ratio of 0.18x, an enterprise value of $853.56K, and an EV/EBITDA multiple of -0.05x. On profitability, it posts a Return on Equity (ROE) of -161.86%, a Return on Assets (ROA) of -116.39%, and a Return on Invested Capital (ROIC) of -154.48%. Per share, it reports EPS of $-16.79, diluted EPS of $-16.79, free cash flow per share of $-5.06, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -67.99% year-over-year and EPS growth of -95.48% year-over-year. On the balance sheet, it maintains a current ratio of 2.55x, a quick ratio of 0.26x, working capital of $5.19M, a debt-to-equity ratio of 0.36x, a debt ratio of 0.26, an interest coverage ratio of -42.24x, free cash flow of $-5.69M (TTM), and net debt of $-832.01K. Figures sourced from SEC EDGAR.
- Market Cap
- $1.69M
- P/E TTM
- -0.09x
- EPS TTM
- $-16.79
- P/B TTM
- 0.18x
- ROE TTM
- -161.86%
- ROA TTM
- -116.39%
- Debt To Equity
- 0.36x
- Free Cash Flow TTM
- $-5.69M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Propanc Biopharma, Inc. in?
Propanc Biopharma, Inc. (PPCB) operates in the Pharmaceutical Preparations industry.
What exchange does PPCB trade on?
Propanc Biopharma, Inc. (PPCB) trades on the Nasdaq.
Where is Propanc Biopharma, Inc. incorporated?
Propanc Biopharma, Inc. is incorporated in DE.
When was Propanc Biopharma, Inc. (PPCB)'s most recent SEC filing?
Propanc Biopharma, Inc. (PPCB)'s most recent SEC filing is a Form 10-K for the period ended 2026-06-30, filed with the SEC on 2026-09-25.
What is PPCB's market cap?
Propanc Biopharma, Inc. (PPCB) has a market capitalization of $1.69M as of 2026-06-30.
What is PPCB's EPS (earnings per share)?
Propanc Biopharma, Inc. (PPCB)'s trailing twelve month EPS is $-16.79 as of 2026-06-30.
What is PPCB's ROE (return on equity)?
Propanc Biopharma, Inc. (PPCB)'s trailing twelve month Return on Equity (ROE) is -161.86% as of 2026-06-30.
What is PPCB's ROA (return on assets)?
Propanc Biopharma, Inc. (PPCB)'s trailing twelve month Return on Assets (ROA) is -116.39% as of 2026-06-30.
What is PPCB's ROIC (return on invested capital)?
Propanc Biopharma, Inc. (PPCB)'s trailing twelve month Return on Invested Capital (ROIC) is -154.48% as of 2026-06-30.
What is PPCB's EV/EBITDA?
Propanc Biopharma, Inc. (PPCB)'s trailing twelve month EV/EBITDA is -0.05x as of 2026-06-30.